

Pathobiology of the Klotho Antiaging Protein and Therapeutic Considerations

Gérald J Prud'homme^{1 2}, Mervé Kurt², Qinghua Wang^{3 4}

Affiliations [expand](#)

PMID: 35903083 PMCID: [PMC9314780](#) DOI: [10.3389/fragi.2022.931331](#)

Abstract

The α -Klotho protein (henceforth denoted Klotho) has antiaging properties, as first observed in mice homozygous for a hypomorphic *Klotho* gene (*kl/kl*). These mice have a shortened lifespan, stunted growth, renal disease, hyperphosphatemia, hypercalcemia, vascular calcification, cardiac hypertrophy, hypertension, pulmonary disease, cognitive impairment, multi-organ atrophy and fibrosis. Overexpression of Klotho has opposite effects, extending lifespan. In humans, Klotho levels decline with age, chronic kidney disease, diabetes, Alzheimer's disease and other conditions. Low Klotho levels correlate with an increase in the death rate from all causes. Klotho acts either as an obligate coreceptor for fibroblast growth factor 23 (FGF23), or as a soluble pleiotropic endocrine hormone (s-Klotho). It is mainly produced in the kidneys, but also in the brain, pancreas and other tissues. On renal tubular-cell membranes, it associates with FGF receptors to bind FGF23. Produced in bones, FGF23 regulates renal excretion of phosphate (phosphaturic effect) and vitamin D metabolism. Lack of Klotho or FGF23 results in hyperphosphatemia and hypervitaminosis D. With age, human renal function often deteriorates, lowering Klotho levels. This appears to promote age-related pathology. Remarkably, Klotho inhibits four pathways that have been linked to aging in various ways: Transforming growth factor β (TGF- β), insulin-like growth factor 1 (IGF-1), Wnt and NF- κ B. These can induce cellular senescence, apoptosis, inflammation, immune dysfunction, fibrosis and neoplasia. Furthermore, Klotho increases cell-protective antioxidant enzymes through Nrf2 and FoxO. In accord, preclinical Klotho therapy ameliorated renal, cardiovascular, diabetes-related and neurodegenerative diseases, as well as cancer. s-Klotho protein injection was effective, but requires further investigation. Several drugs enhance circulating Klotho levels, and some cross the blood-brain barrier to potentially act in the brain. In clinical trials, increased Klotho was noted with renin-angiotensin system

inhibitors (losartan, valsartan), a statin (fluvastatin), mTOR inhibitors (rapamycin, everolimus), vitamin D and pentoxifylline. In preclinical work, antidiabetic drugs (metformin, GLP-1-based, GABA, PPAR- γ agonists) also enhanced Klotho. Several traditional medicines and/or nutraceuticals increased Klotho in rodents, including astaxanthin, curcumin, ginseng, ligustilide and resveratrol. Notably, exercise and sport activity increased Klotho. This review addresses molecular, physiological and therapeutic aspects of Klotho.

Keywords: FGF23; IGF-1; NF-KappaB; TGF-beta; Wnt; aging; hyperphosphatemia; klotho.

Copyright © 2022 Prud'homme, Kurt and Wang.

[PubMed Disclaimer](#)

Conflict of interest statement

Author QW was employed by the company Shanghai Yinuo Pharmaceutical Co., Ltd. QW holds GLP-1 related patents. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Similar articles

Soluble Klotho causes hypomineralization in Klotho-deficient mice.

Minamizaki T, Konishi Y, Sakurai K, Yoshioka H, Aubin JE, Kozai K, Yoshiko Y. *J Endocrinol*. 2018 Jun;237(3):285-300. doi: 10.1530/JOE-17-0683. Epub 2018 Apr 9.

PMID: 29632215

Impact of Altered Mineral Metabolism on Pathological Cardiac Remodeling in Elevated Fibroblast Growth Factor 23.

Leifheit-Nestler M, Richter B, Basaran M, Nespore J, Vogt I, Alesutan I, Voelkl J, Lang F, Heineke J, Krick S, Haffner D.

Front Endocrinol (Lausanne). 2018 Jun 21;9:333. doi: 10.3389/fendo.2018.00333. eCollection 2018.

PMID: 29977226 **Free PMC article.**

Klotho gene, phosphocalcic metabolism, and survival in dialysis.

Torres PU, Prié D, Beck L, De Brauwere D, Leroy C, Friedlander G.

J Ren Nutr. 2009 Jan;19(1):50-6. doi: 10.1053/j.jrn.2008.10.018.

PMID: 19121771 **Review.**

Klotho expression in long bones regulates FGF23 production during renal failure.

Kaludjerovic J, Komaba H, Sato T, Erben RG, Baron R, Olauson H, Larsson TE, Lanske B.

FASEB J. 2017 May;31(5):2050-2064. doi: 10.1096/fj.201601036R. Epub 2017 Feb 9.

PMID: 28183805

Overview of the FGF23-Klotho axis.

Kuro-o M.

Pediatr Nephrol. 2010 Apr;25(4):583-90. doi: 10.1007/s00467-009-1260-4. Epub 2009 Jul 22.

PMID: 19626341 Review.

[See all similar articles](#)

Cited by

Exogenous Klotho Extends Survival in COVID-19 Model Mice.

Alem F, Campos-Obando N, Narayanan A, Bailey CL, Macaya RF.

Pathogens. 2023 Nov 29;12(12):1404. doi: 10.3390/pathogens12121404.

PMID: 38133288 **Free PMC article.**

Relationship of the bone phenotype of the Klotho mutant mouse model of accelerated aging to changes in skeletal architecture that occur with chronological aging.

Verlinden L, Li S, Veldurthy V, Carmeliet G, Christakos S.

Front Endocrinol (Lausanne). 2024 Jan 30;15:1310466. doi: 10.3389/fendo.2024.1310466. eCollection 2024.

PMID: 38352710 [Free PMC article.](#)

Systematic Mendelian Randomization Exploring Druggable Genes for Hemorrhagic Strokes.

Yang LZ, Yang Y, Hong C, Wu QZ, Shi XJ, Liu YL, Chen GZ.

Mol Neurobiol. 2025 Feb;62(2):1359-1372. doi: 10.1007/s12035-024-04336-9. Epub 2024 Jul 9.

PMID: 38977622 [Free PMC article.](#)

The Circulating Level of Klotho Is Not Dependent upon Physical Fitness and Age-Associated Methylation Increases at the Promoter Region of the Klotho Gene.

Aczel D, Torma F, Jokai M, McGreevy K, Boros A, Seki Y, Boldogh I, Horvath S, Radak Z.

Genes (Basel). 2023 Feb 19;14(2):525. doi: 10.3390/genes14020525.

PMID: 36833453 [Free PMC article.](#)

α -Klotho levels in girls with central precocious puberty: potential as a diagnostic and monitoring marker.

Park JH, Noh ES, Hwang IT.

Front Endocrinol (Lausanne). 2024 Apr 8;15:1383812. doi:

10.3389/fendo.2024.1383812. eCollection 2024.

PMID: 38650713 **Free PMC article.**

[See all "Cited by" articles](#)

References

1. Aashaq S., Batool A., Mir S. A., Beigh M. A., Andrabi K. I., Shah Z. A. (2022). TGF- β Signaling: A Recap of SMAD-independent and SMAD-dependent Pathways. *J. Cell. Physiology* 237 (1), 59–85. 10.1002/jcp.30529 - [DOI](#) - [PubMed](#)
2. Abolghasemi M., Yousefi T., Maniati M., Qujeq D. (2019). The Interplay of Klotho with Signaling Pathway and microRNAs in Cancers. *J Cell. Biochem.* 120 (9), 14306–14317. 10.1002/jcb.29022 - [DOI](#) - [PubMed](#)
3. Abramovitz L., Rubinek T., Ligumsky H., Bose S., Barshack I., Avivi C., et al. (2011). KL1 Internal Repeat Mediates Klotho Tumor Suppressor Activities and Inhibits bFGF and IGF-I Signaling in Pancreatic Cancer. *Clin. Cancer Res.* 17 (13), 4254–4266. 10.1158/1078-0432.CCR-10-2749 - [DOI](#) - [PubMed](#)
4. Adeli S., Zahmatkesh M., Tavoosidana G., Karimian M., Hassanzadeh G. (2017). Simvastatin Enhances the Hippocampal Klotho in a Rat Model of Streptozotocin-Induced Cognitive Decline. *Prog. Neuro-Psychopharmacology Biol. Psychiatry* 72, 87–94. 10.1016/j.pnpbp.2016.09.009 - [DOI](#) - [PubMed](#)
5. Ali M. F., Venkatarayappa S. K. B., Benny M., Rojas C., Yousefi K., Shehadeh L. A., et al. (2020). Effects of Klotho Supplementation on Hyperoxia-Induced Renal Injury in a Rodent Model of Postnatal Nephrogenesis. *Pediatr. Res.* 88, 565–570. 10.1038/s41390-020-0803-z - [DOI](#) - [PMC](#) - [PubMed](#)

Show all 266 references

Publication types

[Review](#)

Related information

[MedGen](#)

LinkOut - more resources

Full Text Sources

[Europe PubMed Central](#)

[Frontiers Media SA](#)

[PubMed Central](#)

Other Literature Sources

[The Lens - Patent Citations Database](#)

Miscellaneous

[NCI CPTAC Assay Portal](#)